LifeStance Health operates one of the largest outpatient mental health networks in the US, delivering psychotherapy and psychiatric medication management through employed clinicians and affiliated practices across most states. The model's edge is scale in a fragmented, supply-constrained market where patient demand for behavioral health care has outrun clinician capacity, and the company's platform lets it add providers faster than smaller independents can. Revenue growth of 26.1% is the figure to focus on, showing the network is still expanding its footprint and patient volumes rather than just raising prices. Profitability is early: a 7.2% operating margin and 33.6% gross margin leave room for operating leverage as clinician utilization rises, though a 3.4% ROE and a 95.2 trailing P/E mean the market is paying up for that improvement. At a 52.6 forward P/E the thesis rests on margin expansion arriving on schedule, so the deeper look should test clinician productivity, reimbursement trends and payer mix before anything else.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 19 Oct 2026, 18:04 CEST | Rating | Overvalued | first publication | $11.74 |
| 19 Oct 2026, 18:04 CEST | Fair value | $6.37 | $6.27 | $11.74 |
| 11 Oct 2026, 00:00 CEST | ACCE price target | $13.00 | first publication | $12.42 |
| 11 Oct 2026, 00:00 CEST | Fair value | $6.27 | $2.38 | $12.42 |
| 7 Oct 2026, 00:00 CEST | Fair value | $2.38 | $2.31 | $12.22 |
| 4 Oct 2026, 00:00 CEST | Fair value | $2.31 | $2.35 | $11.83 |
| 28 Sept 2026, 00:00 CEST | Fair value | $2.35 | $2.29 | $11.84 |
| 25 Sept 2026, 00:00 CEST | Fair value | $2.29 | $2.38 | $12.08 |
| 21 Sept 2026, 00:00 CEST | Fair value | $2.38 | $2.33 | $12.57 |
| 18 Sept 2026, 00:00 CEST | Fair value | $2.33 | $2.43 | $12.79 |
Answered from LifeStance Health Group Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| LFST LifeStance Health Group Inc. Common Stock | $12.93 | $6 | 103% above | 96.6x | 3.4% | 51 | 65 |
| OPCH Option Care Health Inc. Common Stock | $31.22 | $34 | 8% below | 23.7x | 16.0% | 48 | 58 |
| CON Concentra Group Holdings Parent Inc. Common Stock | $39.25 | $27 | 47% above | 25.3x | 47.1% | 64 | 74 |
| MCOV-B.ST Medicover AB (publ) | kr 276.00 | kr 176 | 57% above | 45.2x | 15.5% | 43 | 54 |
| FORTIS.NS Fortis Healthcare Limited | ₹712.90 | - | - | 51.4x | - | 76 | 45 |
| ASTERDM.NS Aster DM Quality Care Limited | ₹644.75 | - | - | 104.5x | - | 71 | 44 |
| NHC National HealthCare Corporation | $236.01 | $236 | At fair value | 27.3x | 13.3% | 68 | 77 |
Where LFST ranks against its sector peers on each metric.